RetaMaps

Northern Westchester Hospital Surgical Weight Loss Program

Northwell Health Physician Partners Surgical Specialties at Chappaqua · 480 Bedford Road · Chappaqua, NY 10514

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Northern Westchester Hospital’s Surgical Weight Loss Program (Northwell Health) is an MBSAQIP-accredited metabolic and bariatric surgery service in Westchester County, NY, with appointments through Physician Partners Surgical Specialties at Chappaqua (480 Bedford Road). Led by Mitchell Roslin, MD, and Amanda Messina, MD, it offers gastric bypass, sleeve gastrectomy, lap-band, duodenal switch/SADI-S, and revisions, plus dietitian and psychology support and an accredited adolescent program. Official pages describe surgical weight loss, not a named GLP-1 medication clinic.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visits—
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Clinicians

  • Mitchell Roslin, MD, FACS, FASMBS
  • Amanda Messina, MD, FACS

Nearby providers in Chappaqua

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs